Luis M. de la Torre-Fonseca, Unidad de Cuidados Intensivos, Hospital Universitario Clínico Quirúrgico Comandante Manuel Fajardo; Facultad de Ciencias Médicas Manuel Fajardo, Universidad de Ciencias Médicas de La Habana. La Habana, Cuba
Ronald E. Pucha-Pesántez, Servicio de Cardiología, Hospital IESS Los Ceibos, Ecuador
Adrián M. Pacheco-Naranjo, Servicio de Cardiología, Hospital Clínica San Francisco, Ecuador
Rubén A. Guamán-Castro, Servicio de Emergencia, Clínica Sur Hospital, Ecuador
Diego G. Delgado-Intriago, Servicio de Cardiología, Hospital Regional Dr. Verdi Cevallos Balda de Portoviejo, Portoviejo, Manabí, Ecuador
Robert Alarcón-Cedeño, Servicio de Hemodinámica, Hospital Álvaro Cunqueiro, Área Sanitaria de Vigo, SERGAS, Vigo, Pontevedra, España
Drug-eluting balloons have emerged as a promising treatment option for various coronary artery disease presentations due to their ability to deliver antiproliferative drugs directly to the vessel wall without leaving behind permanent implants. This rapid and homogeneous drug delivery effectively reduces restenosis risk and facilitates vessel healing, while minimizing the likelihood of late thrombotic events. Clinical studies have consistently demonstrated the efficacy and safety of drug-eluting balloons in treating a wide range of coronary artery disease conditions, including de novo lesions, in-stent restenosis, small vessel lesions, and bifurcation lesions. Compared to conventional stents, drug-eluting balloons have consistently shown lower restenosis rates in the medium and long term without increasing the risk of thrombotic complications, making them an attractive alternative for patients with coronary artery disease, particularly those at higher risk of restenosis or stent thrombosis.
Keywords: Drug-eluting balloon. Drug-eluting stent. Coronary artery disease. Coronary restenosis.
